Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtrer
1.
Clin Cancer Res ; 29(16): 3051-3064, 2023 08 15.
Article de Anglais | MEDLINE | ID: mdl-37058257

RÉSUMÉ

PURPOSE: Tumor hypoxia is a paradigmatic negative prognosticator of treatment resistance in head and neck squamous cell carcinoma (HNSCC). The lack of robust and reliable hypoxia classifiers limits the adaptation of stratified therapies. We hypothesized that the tumor DNA methylation landscape might indicate epigenetic reprogramming induced by chronic intratumoral hypoxia. EXPERIMENTAL DESIGN: A DNA-methylome-based tumor hypoxia classifier (Hypoxia-M) was trained in the TCGA (The Cancer Genome Atlas)-HNSCC cohort based on matched assignments using gene expression-based signatures of hypoxia (Hypoxia-GES). Hypoxia-M was validated in a multicenter DKTK-ROG trial consisting of human papillomavirus (HPV)-negative patients with HNSCC treated with primary radiochemotherapy (RCHT). RESULTS: Although hypoxia-GES failed to stratify patients in the DKTK-ROG, Hypoxia-M was independently prognostic for local recurrence (HR, 4.3; P = 0.001) and overall survival (HR, 2.34; P = 0.03) but not distant metastasis after RCHT in both cohorts. Hypoxia-M status was inversely associated with CD8 T-cell infiltration in both cohorts. Hypoxia-M was further prognostic in the TCGA-PanCancer cohort (HR, 1.83; P = 0.04), underscoring the breadth of this classifier for predicting tumor hypoxia status. CONCLUSIONS: Our findings highlight an unexplored avenue for DNA methylation-based classifiers as biomarkers of tumoral hypoxia for identifying high-risk features in patients with HNSCC tumors. See related commentary by Heft Neal and Brenner, p. 2954.


Sujet(s)
Carcinome épidermoïde , Tumeurs de la tête et du cou , Infections à papillomavirus , Humains , Carcinome épidermoïde de la tête et du cou/génétique , Carcinome épidermoïde de la tête et du cou/thérapie , Carcinome épidermoïde/génétique , Carcinome épidermoïde/thérapie , Carcinome épidermoïde/mortalité , Hypoxie tumorale/génétique , Infections à papillomavirus/complications , Infections à papillomavirus/génétique , Infections à papillomavirus/virologie , Épigénome , Récidive tumorale locale/génétique , Tumeurs de la tête et du cou/génétique , Tumeurs de la tête et du cou/thérapie , Pronostic , Chimioradiothérapie , Hypoxie/génétique , ADN
2.
STAR Protoc ; 3(4): 101798, 2022 12 16.
Article de Anglais | MEDLINE | ID: mdl-36340882

RÉSUMÉ

We present a protocol for the biosensor Cell-Fit-HD4D. It enables long-term monitoring and correlation of single-cell fate with subcellular-deposited energy of ionizing radiation. Cell fate tracking using widefield time-lapse microscopy is uncoupled in time from confocal ion track imaging. Registration of both image acquisition steps allows precise ion track assignment to cells and correlation with cellular readouts. For complete details on the use and execution of this protocol, please refer to Niklas et al. (2022).


Sujet(s)
Techniques de biocapteur , Transfert linéique d'énergie , Microscopie confocale/méthodes , Radiométrie/méthodes , Suivi cellulaire
3.
Cell Rep Methods ; 2(2): 100169, 2022 02 28.
Article de Anglais | MEDLINE | ID: mdl-35474967

RÉSUMÉ

Clonogenic survival assay constitutes the gold standard method for quantifying radiobiological effects. However, it neglects cellular radiation response variability and heterogeneous energy deposition by ion beams on the microscopic scale. We introduce "Cell-Fit-HD4D" a biosensor that enables a deconvolution of individual cell fate in response to the microscopic energy deposition as visualized by optical microscopy. Cell-Fit-HD4D enables single-cell dosimetry in clinically relevant complex radiation fields by correlating microscopic beam parameters with biological endpoints. Decrypting the ion beam's energy deposition and molecular effects at the single-cell level has the potential to improve our understanding of radiobiological dose concepts as well as radiobiological study approaches in general.


Sujet(s)
Techniques de biocapteur , Radiothérapie par ions lourds , Radiométrie/méthodes , Radiothérapie par ions lourds/méthodes
4.
Radiol Artif Intell ; 4(2): e210095, 2022 Mar.
Article de Anglais | MEDLINE | ID: mdl-35391764

RÉSUMÉ

Purpose: To develop a model to accurately segment mouse lungs with varying levels of fibrosis and investigate its applicability to mouse images with different resolutions. Materials and Methods: In this experimental retrospective study, a U-Net was trained to automatically segment lungs on mouse CT images. The model was trained (n = 1200), validated (n = 300), and tested (n = 154) on longitudinally acquired and semiautomatically segmented CT images, which included both healthy and irradiated mice (group A). A second independent group of 237 mice (group B) was used for external testing. The Dice score coefficient (DSC) and Hausdorff distance (HD) were used as metrics to quantify segmentation accuracy. Transfer learning was applied to adapt the model to high-spatial-resolution mouse micro-CT segmentation (n = 20; group C [n = 16 for training and n = 4 for testing]). Results: The trained model yielded a high median DSC in both test datasets: 0.984 (interquartile range [IQR], 0.977-0.988) in group A and 0.966 (IQR, 0.955-0.972) in group B. The median HD in both test datasets was 0.47 mm (IQR, 0-0.51 mm [group A]) and 0.31 mm (IQR, 0.30-0.32 mm [group B]). Spatially resolved quantification of differences toward reference masks revealed two hot spots close to the air-tissue interfaces, which are particularly prone to deviation. Finally, for the higher-resolution mouse CT images, the median DSC was 0.905 (IQR, 0.902-0.929) and the median 95th percentile of the HD was 0.33 mm (IQR, 2.61-2.78 mm). Conclusion: The developed deep learning-based method for mouse lung segmentation performed well independently of disease state (healthy, fibrotic, emphysematous lungs) and CT resolution.Keywords: Deep Learning, Lung Fibrosis, Radiation Therapy, Segmentation, Animal Studies, CT, Thorax, Lung Supplemental material is available for this article. Published under a CC BY 4.0 license.

5.
Int J Cancer ; 150(4): 603-616, 2022 02 15.
Article de Anglais | MEDLINE | ID: mdl-34648658

RÉSUMÉ

Biomarkers with relevance for loco-regional therapy are needed in human papillomavirus negative aka HPV(-) head and neck squamous cell carcinoma (HNSCC). Based on the premise that DNA methylation pattern is highly conserved, we sought to develop a reliable and robust methylome-based classifier identifying HPV(-) HNSCC patients at risk for loco-regional recurrence (LR) and all-event progression after postoperative radiochemotherapy (PORT-C). The training cohort consisted of HPV-DNA negative HNSCC patients (n = 128) homogeneously treated with PORT-C in frame of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA Methylation analysis was performed using Illumina 450 K and 850 K-EPIC microarray technology. The performance of the classifier was integrated with a series of biomarkers studied in the training set namely hypoxia-, 5-microRNA (5-miR), stem-cell gene-expression signatures and immunohistochemistry (IHC)-based immunological characterization of tumors (CD3/CD8/PD-L1/PD1). Validation occurred in an independent cohort of HPV(-) HNSCC patients, pooled from two German centers (n = 125). We identified a 38-methylation probe-based HPV(-) Independent Classifier of disease Recurrence (HICR) with high prognostic value for LR, distant metastasis and overall survival (P < 10-9 ). HICR remained significant after multivariate analysis adjusting for anatomical site, lymph node extracapsular extension (ECE) and size (T-stage). HICR high-risk tumors were enriched for younger patients with hypoxic tumors (15-gene signature) and elevated 5-miR score. After adjustment for hypoxia and 5-miR covariates, HICR maintained predicting all endpoints. HICR provides a novel mean for assessing the risk of LR in HPV(-) HNSCC patients treated with PORT-C and opens a new opportunity for biomarker-assisted stratification and therapy adaptation in these patients.


Sujet(s)
Chimioradiothérapie , Méthylation de l'ADN , ADN tumoral/métabolisme , Tumeurs de la tête et du cou/génétique , Récidive tumorale locale/étiologie , Carcinome épidermoïde de la tête et du cou/génétique , Association thérapeutique , Femelle , Tumeurs de la tête et du cou/immunologie , Tumeurs de la tête et du cou/thérapie , Tumeurs de la tête et du cou/virologie , Humains , Mâle , microARN/analyse , Adulte d'âge moyen , Papillomaviridae/isolement et purification , Carcinome épidermoïde de la tête et du cou/immunologie , Carcinome épidermoïde de la tête et du cou/thérapie , Carcinome épidermoïde de la tête et du cou/virologie
6.
Cancer Cell ; 39(10): 1388-1403.e10, 2021 10 11.
Article de Anglais | MEDLINE | ID: mdl-34506739

RÉSUMÉ

Localized radiotherapy (RT) induces an immunogenic antitumor response that is in part counterbalanced by activation of immune evasive and tissue remodeling processes, e.g., via upregulation of programmed cell death-ligand 1 (PD-L1) and transforming growth factor ß (TGF-ß). We report that a bifunctional fusion protein that simultaneously inhibits TGF-ß and PD-L1, bintrafusp alfa (BA), effectively synergizes with radiotherapy, leading to superior survival in multiple therapy-resistant murine tumor models with poor immune infiltration. The BA + RT (BART) combination increases tumor-infiltrating leukocytes, reprograms the tumor microenvironment, and attenuates RT-induced fibrosis, leading to reconstitution of tumor immunity and regression of spontaneous lung metastases. Consistently, the beneficial effects of BART are in part reversed by depletion of cytotoxic CD8+ T cells. Intriguingly, targeting of the TGF-ß trap to PD-L1+ endothelium and the M2/lipofibroblast-like cell compartment by BA attenuated late-stage RT-induced lung fibrosis. Together, the results suggest that the BART combination has the potential to eradicate therapy-resistant tumors while sparing normal tissue, further supporting its clinical translation.


Sujet(s)
Inhibiteurs de points de contrôle immunitaires/usage thérapeutique , Échappement immunitaire/immunologie , Tumeurs/traitement médicamenteux , Tumeurs/radiothérapie , Facteur de croissance transformant bêta/métabolisme , Animaux , Humains , Inhibiteurs de points de contrôle immunitaires/pharmacologie , Souris , Microenvironnement tumoral
8.
Mol Syst Biol ; 15(12): e8983, 2019 12.
Article de Anglais | MEDLINE | ID: mdl-31885201

RÉSUMÉ

Arrayed CRISPR-based screens emerge as a powerful alternative to pooled screens making it possible to investigate a wide range of cellular phenotypes that are typically not amenable to pooled screens. Here, we describe a solid-phase transfection platform that enables CRISPR-based genetic screens in arrayed format with flexible readouts. We demonstrate efficient gene knockout upon delivery of guide RNAs and Cas9/guide RNA ribonucleoprotein complexes into untransformed and cancer cell lines. In addition, we provide evidence that our platform can be easily adapted to high-throughput screens and we use this approach to study oncogene addiction in tumor cells. Finally demonstrating that the human primary cells can also be edited using this method, we pave the way for rapid testing of potential targeted therapies.


Sujet(s)
Édition de gène/instrumentation , Tumeurs/génétique , /pharmacologie , Systèmes CRISPR-Cas , Lignée cellulaire tumorale , Prédisposition génétique à une maladie , Tests de criblage à haut débit , Humains , Phénotype , Transfection
9.
Cell Death Differ ; 24(11): 1872-1885, 2017 11.
Article de Anglais | MEDLINE | ID: mdl-28708136

RÉSUMÉ

The regulation of chromatin structure is critical for a wide range of essential cellular processes. The Tousled-like kinases, TLK1 and TLK2, regulate ASF1, a histone H3/H4 chaperone, and likely other substrates, and their activity has been implicated in transcription, DNA replication, DNA repair, RNA interference, cell cycle progression, viral latency, chromosome segregation and mitosis. However, little is known about the functions of TLK activity in vivo or the relative functions of the highly similar TLK1 and TLK2 in any cell type. To begin to address this, we have generated Tlk1- and Tlk2-deficient mice. We found that while TLK1 was dispensable for murine viability, TLK2 loss led to late embryonic lethality because of placental failure. TLK2 was required for normal trophoblast differentiation and the phosphorylation of ASF1 was reduced in placentas lacking TLK2. Conditional bypass of the placental phenotype allowed the generation of apparently healthy Tlk2-deficient mice, while only the depletion of both TLK1 and TLK2 led to extensive genomic instability, indicating that both activities contribute to genome maintenance. Our data identifies a specific role for TLK2 in placental function during mammalian development and suggests that TLK1 and TLK2 have largely redundant roles in genome maintenance.


Sujet(s)
Développement embryonnaire , Mammifères/embryologie , Mammifères/métabolisme , Protein kinases/métabolisme , Protein-Serine-Threonine Kinases/métabolisme , Animaux , Protéines du cycle cellulaire , Prolifération cellulaire , Survie cellulaire , Instabilité des chromosomes , Protéines chromosomiques nonhistones , Développement embryonnaire/génétique , Femelle , Régulation de l'expression des gènes au cours du développement , Gènes essentiels , Humains , Souris de lignée C57BL , Chaperons moléculaires , Phosphorylation , Placenta/embryologie , Placenta/métabolisme , Grossesse , Liaison aux protéines , Protein kinases/déficit , Protein-Serine-Threonine Kinases/génétique , Survie tissulaire
10.
Nucleic Acids Res ; 43(15): 7371-87, 2015 Sep 03.
Article de Anglais | MEDLINE | ID: mdl-26160886

RÉSUMÉ

The maintenance of genome stability is critical for the suppression of diverse human pathologies that include developmental disorders, premature aging, infertility and predisposition to cancer. The DNA damage response (DDR) orchestrates the appropriate cellular responses following the detection of lesions to prevent genomic instability. The MRE11 complex is a sensor of DNA double strand breaks (DSBs) and plays key roles in multiple aspects of the DDR, including DNA end resection that is critical for signaling and DNA repair. The MRE11 complex has been shown to function both upstream and in concert with the 5'-3' exonuclease EXO1 in DNA resection, but it remains unclear to what extent EXO1 influences DSB responses independently of the MRE11 complex. Here we examine the genetic relationship of the MRE11 complex and EXO1 during mammalian development and in response to DNA damage. Deletion of Exo1 in mice expressing a hypomorphic allele of Nbs1 leads to severe developmental impairment, embryonic death and chromosomal instability. While EXO1 plays a minimal role in normal cells, its loss strongly influences DNA replication, DNA repair, checkpoint signaling and damage sensitivity in NBS1 hypomorphic cells. Collectively, our results establish a key role for EXO1 in modulating the severity of hypomorphic MRE11 complex mutations.


Sujet(s)
Protéines du cycle cellulaire/génétique , Enzymes de réparation de l'ADN/physiologie , Réparation de l'ADN , Développement embryonnaire , Exodeoxyribonucleases/physiologie , Protéines nucléaires/génétique , Allèles , Animaux , Protéines mutées dans l'ataxie-télangiectasie/métabolisme , Camptothécine/toxicité , Cellules cultivées , Instabilité des chromosomes , Cassures double-brin de l'ADN , Enzymes de réparation de l'ADN/génétique , Réplication de l'ADN , Protéines de liaison à l'ADN , Développement embryonnaire/génétique , Exodeoxyribonucleases/génétique , Points de contrôle de la phase G2 du cycle cellulaire , Délétion de gène , Gènes létaux , Souris , Mutation
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...